<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047771</url>
  </required_header>
  <id_info>
    <org_study_id>CLO-SCB-313-CHN-003</org_study_id>
    <nct_id>NCT04047771</nct_id>
  </id_info>
  <brief_title>A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis</brief_title>
  <official_title>A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of SCB-313, Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Trimer Fusion Protein, for the Treatment of Subjects With Peritoneal Carcinomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Clover Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Clover Biopharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of SCB-313 in patients with peritoneal&#xD;
      carcinomatosisa, to determine the maximum tolerated dose (MTD) and/or extended study&#xD;
      recommended dose (RDE) for SCB-313 intraperitoneal injection, providing a basis for dosing&#xD;
      regimen and dose choosing in clinical trial subsequently.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>21 days after first dosing</time_frame>
    <description>DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>21 days after first dosing</time_frame>
    <description>AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>28 days after last dosing</time_frame>
    <description>Occurrence of binding and neutralizing anti-SCB-313 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Up to 24 hours after dosing</time_frame>
    <description>Maximum SCB-313 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (tmax)</measure>
    <time_frame>Up to 24 hours after dosing</time_frame>
    <description>Time to Cmax of SCB-313</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ([AUC]0-24)</measure>
    <time_frame>Up to 24 hours after dosing</time_frame>
    <description>Area under SCB-313 concentration time curve from zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC 0-inf)</measure>
    <time_frame>Up to 24 hours after dosing</time_frame>
    <description>Area under curve from time 0 extrapolated to infinity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>SCB-313</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCB-313</intervention_name>
    <description>Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle</description>
    <arm_group_label>SCB-313</arm_group_label>
    <other_name>recombinant human TRAIL-Trimer fusion protein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be able to understand and voluntarily sign written informed consent.&#xD;
&#xD;
          2. Male or female subjects, age ≥18, ≤75 years.&#xD;
&#xD;
          3. Confirmed by histopathology or cytopathology, any primary or secondary malignant&#xD;
             peritoneal carcinomatosis subject.&#xD;
&#xD;
          4. Progression after standard treatment, or inability to tolerate standard treatment, or&#xD;
             no standard treatment.&#xD;
&#xD;
          5. ECOG status 0 to 2 or KPS status &gt; 60&#xD;
&#xD;
          6. CT-PCI (Peritoneal Carcinomatosis Index) status ≥ 15&#xD;
&#xD;
          7. Life expectancy of at least 3 months.&#xD;
&#xD;
          8. No serious hematologic, hepatic, renal dysfunction, comply with the following&#xD;
             laboratory test results:&#xD;
&#xD;
               1. Hematology: white blood cell count &gt;3*109/L, absolute neutrophil count&#xD;
                  ≥1.5*109/L, platelets &gt; 75*109/L, hemoglobin &gt; 90 g/L.&#xD;
&#xD;
               2. Liver function: aspartate aminotransferase and alanine aminotransferase ≤ 3 times&#xD;
                  ULN, Alkaline phosphatase (ALP) ≤ 2.5 times ULN; serum total bilirubin (TBIL) ≤&#xD;
                  1.5 times ULN.&#xD;
&#xD;
               3. Renal function: Creatinine clearance calculated according to the Cockcroft-Gault&#xD;
                  formula ≥ 50 mL/min.&#xD;
&#xD;
          9. All adverse events from previous system anticancer treatment return to baseline or ≤&#xD;
             grade 1 (except for alopecia and vitiligo, neuropathy which induced by previous&#xD;
             anticancer therapy status stable or ≤ grade 2).&#xD;
&#xD;
         10. Male or female subjects undergo effective contraception during treatment and within 6&#xD;
             months after last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with TRAIL pathway drug.&#xD;
&#xD;
          2. Malignant cancer diseases other than malignant peritoneal carcinomatosis in this study&#xD;
             (Exceptions include: a cured malignant cancer without relapse within 3 years prior to&#xD;
             the study enrollment, completely resected basal cells and squamous cell skin cancer,&#xD;
             and any type of carcinoma in situ).&#xD;
&#xD;
          3. Primary lesion invades the central nervous system (CNS) with symptoms develop, status&#xD;
             unstable or require high dose steroids (e.g. dexamethasone ≥ 10 mg or equivalent dose)&#xD;
             to control.&#xD;
&#xD;
          4. Abnormal HBV examination, anti-HCV positive, anti-HIV antibody positive or other&#xD;
             serious infections requiring systemic treatment within 4 weeks prior to first dosing&#xD;
             (e.g. virus, bacteria or fungus).&#xD;
&#xD;
          5. Use the following concomitant therapy before dosing:&#xD;
&#xD;
               1. Use drug that prolongs the QT interval and/or associated with the risk of&#xD;
                  torsades de pointes ventricular tachycardia (TdP) within 7 days prior to first&#xD;
                  dosing.&#xD;
&#xD;
               2. Use amiodarone within 90 days prior to first dosing.&#xD;
&#xD;
          6. Impaired heart function or clinically significant cardiovascular disease, including&#xD;
             any of the following:&#xD;
&#xD;
               1. Cerebrovascular accident/stroke (within 6 months prior to enrollment).&#xD;
&#xD;
               2. Myocardial infarction (within 6 months prior to enrollment).&#xD;
&#xD;
               3. Unstable angina, congestive heart failure (New York Heart Association grade ≥ II)&#xD;
                  or severe arrhythmia requiring medication (including QT/QTc interval extension&#xD;
                  &gt;480 msec, installation of pacemakers, etc.).&#xD;
&#xD;
               4. Left ventricular ejection fraction &lt; 50% as determined by echocardiography.&#xD;
&#xD;
          7. Active bleeding history or gastrointestinal perforation risk within 4 weeks before&#xD;
             enrollment, or not healed from recent surgery.&#xD;
&#xD;
          8. Received anticancer treatment within following specified time before first dosing:&#xD;
&#xD;
               1. Received medical treatment ≤ 4 weeks or 5 times known drug half-life (whichever&#xD;
                  is longer).&#xD;
&#xD;
               2. Underwent major surgery within ≤ 4 weeks before first dosing.&#xD;
&#xD;
          9. Residual adverse events from previous treatment≥ grade 2.&#xD;
&#xD;
         10. Known to have alcohol and/or drug dependence.&#xD;
&#xD;
         11. Previous clear history of neurological or mental disorders, such as epilepsy, poor&#xD;
             compliance&#xD;
&#xD;
         12. Female subjects with positive blood pregnancy tests or during lactation.&#xD;
&#xD;
         13. Previously allergic to macromolecular protein drugs or proteins or Quincke's edema&#xD;
             (Kunke edema, also known as angioedema) or allergic to any component of the SCB 313.&#xD;
&#xD;
         14. Known history of infection with human immunodeficiency virus, or other acquired,&#xD;
             innate immune deficiency diseases, or history of organ transplantation.&#xD;
&#xD;
         15. Vaccination within ≤ 4 weeks prior to first dosing, or planning live vaccination.&#xD;
&#xD;
         16. For other reasons according to investigators, not suitable for participation in the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqing Bao</last_name>
      <phone>+8613701174871</phone>
      <email>olivia.bao@cloverbiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

